Huyen Cao

Public Health Dayton & Montgomery County — United States

Immunology and Microbiology · Life Sciences

34h-index9.5kcitations95works7.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(48), HIV/AIDS Research and Interventions(29), HIV/AIDS drug development and treatment(23), COVID-19 Clinical Research Studies(20), Immune Cell Function and Interaction(15)

Publications86 total

A Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy
Health Security·2025· 2 citedOpen Access
Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs
Clinical Infectious Diseases·2024· 3 citedOpen Access
Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments
Journal of Virology·2024· 15 citedOpen Access
<span>Measures to build material environment for children aged 5-6 to discover science at kindergarten schools in Lap Vo district, Dong Thap province</span>
Dong Thap University Journal of Science·2023Open Access
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Intensive Care Medicine·2021· 124 citedOpen Access
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
2021· 5 citedOpen Access
Compassionate Use of Remdesivir in Children With Severe COVID-19
PEDIATRICS·2021· 103 cited
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
Clinical Pharmacokinetics·2021· 131 citedOpen Access
PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors
Clinical Infectious Diseases·2021· 40 citedOpen Access
Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
Antimicrobial Agents and Chemotherapy·2021· 2 citedOpen Access
548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
Open Forum Infectious Diseases·2020· 3 citedOpen Access
561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
Open Forum Infectious Diseases·2020· 5 citedOpen Access
72. Remdesivir vs Standard Care in Patients with Moderate covid-19
Open Forum Infectious Diseases·2020· 2 citedOpen Access
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
JAMA·2020· 1.3k citedOpen Access
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
Clinical and Translational Science·2020· 261 citedOpen Access
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine·2020· 1.4k citedOpen Access
Compassionate Use of Remdesivir for Patients with Severe Covid-19
New England Journal of Medicine·2020· 2.9k citedOpen Access
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
JAIDS Journal of Acquired Immune Deficiency Syndromes·2019· 54 citedOpen Access
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women
JAIDS Journal of Acquired Immune Deficiency Syndromes·2018· 18 citedOpen Access
Lack of clinically important<scp>PK</scp>interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide
Pharmacology Research & Perspectives·2017· 15 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Norman G. Jones(13), Mohamed Elrefaei(10), David R. Bangsberg(8), Peter Mugyenyi(7), Chris A. R. Baker(7), Anu Osinusi(6), Edwin DeJesus(6), Andrew Cheng(6), Banson Barugahare(6), Cissy Kityo(6), Diana M. Brainard(5), Ellen Koenig(5), Isaac Ssewanyana(5), Moses R. Kamya(5), Stephanie Bousheri(5), Devi SenGupta(4), Gordon Crofoot(4), Jeffrey N. Martin(4), George Diaz(3), Anuj Gaggar(3)